Chimeric Antigen Receptor-T Cell Mediated Bilateral Facial Nerve Palsy: A Case Report.
Natalya PatrickNizar BahlisSteven R PetersPublished in: The Neurohospitalist (2023)
Chimeric antigen receptor (CAR-T) cell therapy is highly effective against hematological cancers but is associated with immune mediated side effects, including neurotoxicity. The most commonly described presentations of immune cell mediated neurotoxicity syndrome (ICANS) include cortical symptoms and generally localize to the central nervous system. In this report, we present a patient with acute onset of bilateral facial nerve palsy following CAR-T cell therapy, followed by a complete clinical recovery. Aside from a temporary anisocoria, he had no other neurologic symptoms and no encephalopathy or seizures. MRI Brain was non-contributory and cerebrospinal fluid revealed a modest increase in lymphocytes without systemic leukocytosis and viral studies were all negative. He was diagnosed with bilateral facial nerve palsy secondary to CAR-T cell therapy and subsequently treated with a course of steroids. Several weeks after presentation he returned to his neurological baseline. The presentation of CAR-T cell mediated facial nerve palsy is both clinically and scientifically relevant for physicians, patients, and researchers.
Keyphrases
- cell therapy
- case report
- stem cells
- cerebrospinal fluid
- mesenchymal stem cells
- peripheral nerve
- soft tissue
- end stage renal disease
- newly diagnosed
- primary care
- magnetic resonance imaging
- ejection fraction
- chronic kidney disease
- prognostic factors
- liver failure
- computed tomography
- contrast enhanced
- sleep quality
- single cell
- peripheral blood
- multiple sclerosis
- blood brain barrier
- respiratory failure
- gestational age
- acute respiratory distress syndrome
- bone marrow
- diffusion weighted imaging
- preterm birth
- extracorporeal membrane oxygenation